Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
RA Rudick, CH Polman - The Lancet Neurology, 2009 - thelancet.com
Disease-modifying drugs (DMDs) for relapsing-remitting multiple sclerosis (RRMS) are only
partly effective—breakthrough disease commonly occurs despite treatment. Breakthrough …
partly effective—breakthrough disease commonly occurs despite treatment. Breakthrough …
Personalised medicine for multiple sclerosis care
A Gafson, MJ Craner… - Multiple Sclerosis …, 2017 - journals.sagepub.com
Treatments with a range of efficacy and risk of adverse events have become available for the
management of multiple sclerosis (MS). However, now the heterogeneity of clinical …
management of multiple sclerosis (MS). However, now the heterogeneity of clinical …
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
CH Polman, A Bertolotto, F Deisenhammer… - The Lancet …, 2010 - thelancet.com
The identification of factors that can affect the efficacy of immunomodulatory drugs in
relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta …
relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta …
Using serum metabolomics to predict development of anti-drug antibodies in multiple sclerosis patients treated with IFNβ
KE Waddington, A Papadaki, L Coelewij… - Frontiers in …, 2020 - frontiersin.org
Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of
biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the …
biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the …
Determinants of interferon β efficacy in patients with multiple sclerosis
J Killestein, CH Polman - Nature reviews Neurology, 2011 - nature.com
Many patients with multiple sclerosis (MS) experience clinical relapses or progression of
disability, or exhibit evidence of disease activity on MRI, despite the use of disease …
disability, or exhibit evidence of disease activity on MRI, despite the use of disease …
Neutralizing antibodies to interferon-β and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes
F Deisenhammer - CNS drugs, 2009 - Springer
Biopharmaceuticals can induce antibodies, which interact with and neutralize the
therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In …
therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In …
Antidrug antibodies against biological treatments for multiple sclerosis
PS Sorensen - CNS drugs, 2022 - Springer
The development of antidrug antibodies (ADAs) is a major problem in several recombinant
protein therapies used in the treatment of multiple sclerosis (MS). The etiology of ADAs is …
protein therapies used in the treatment of multiple sclerosis (MS). The etiology of ADAs is …
Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis
J Link, M Lundkvist Ryner, K Fink, C Hermanrud… - PLoS …, 2014 - journals.plos.org
A significant proportion of patients with multiple sclerosis who receive interferon beta (IFNβ)
therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if …
therapy develop neutralizing antibodies (NAbs) that reduce drug efficacy. To investigate if …
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development
H Hegen, A Millonig, A Bertolotto… - Multiple Sclerosis …, 2014 - journals.sagepub.com
Background: Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment
in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually …
in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually …
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: a descriptive study of test results
J Link, R Ramanujam, M Auer, M Ryner, S Hässler… - PLoS …, 2017 - journals.plos.org
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-
integrated part of the clinical care of multiple sclerosis (MS) in several European countries …
integrated part of the clinical care of multiple sclerosis (MS) in several European countries …